REGENXBIO Inc. REGENXBIO Inc.

REGENXBIO Inc.

RGNX

Rank in Stocks #12137
REGENXBIO Inc. is a biotechnology company operating in the clinical stage,... REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. The company's primary investigational asset, RGX-314, is currently in Phase III clinical trials for treating wet age-related macular degeneration. Its pipeline also includes RGX-121 and RGX-111, both in Phase I/II trials for mucopolysaccharidosis type II and type I, respectively; RGX-181, which is in preclinical development for late-infantile neuronal ceroid lipofuscinosis type II disease; RGX-202, undergoing Phase I/II evaluation for Duchenne muscular dystrophy; and RGX-381, at the preclinical stage for addressing the ocular manifestations of CLN2 disease. In addition to its internal programs, REGENXBIO Inc. licenses its NAV Technology Platform to other biotech and pharmaceutical enterprises. It also maintains a collaborative and licensing agreement with Neurimmune AG for the advancement of innovative gene therapies. Founded in 2008, REGENXBIO Inc. maintains its headquarters in Rockville, Maryland.
Share Price
$7.16
Last synced: 2026-11-20
Market Cap
$467.28M
Change (1 day)
-0.28%
Change (1 year)
-39.32%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
Operating Margin for REGENXBIO Inc. (RGNX)
Operating Margin as of November 2026 TTM: -95.68%
According to REGENXBIO Inc.'s latest financial reports, its current operating margin (TTM) is -95.68%. At the end of 2025 the company had an operating margin of -94.58%.
Operating Margin history for REGENXBIO Inc. from 2013 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) -95.68% 1.16%
2025 -94.58% -66.23%
2024 -280.03% -5.75%
2023 -297.12% 27.41%
2022 -233.20% -785.68%
2021 34.01% -144.09%
2020 -77.14% -81.76%
2019 -422.89% -1,148.83%
2018 40.32% -105.52%
2017 -730.15% -48.72%
2016 -1,423.84% 366.96%
2015 -304.92% 406.85%
2014 -60.16% -23.32%
2013 -78.46% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
33.87% -100.35%
US
-116.04% -98.79%
US
25.57% -100.27%
AU
29.35% -100.31%
NL
31.23% -100.33%
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.

Questions about REGENXBIO Inc.'s operating margin

What is REGENXBIO Inc.'s operating margin?

REGENXBIO Inc.'s operating margin is -95.68%, as of Nov 2026.

What was REGENXBIO Inc.'s operating margin in 2025?

In 2025, REGENXBIO Inc.'s operating margin was -94.58%, compared with -280.03% in 2024.

How has REGENXBIO Inc.'s operating margin changed since 2020?

From 2020 to 2025, REGENXBIO Inc.'s operating margin was highest in 2021 (34.01%) and lowest in 2023 (-297.12%).

How does REGENXBIO Inc.'s operating margin compare with similar companies?

REGENXBIO Inc.'s operating margin (-95.68%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.